<DOC>
	<DOCNO>NCT00040742</DOCNO>
	<brief_summary>RATIONALE : Ginger may help reduce prevent nausea . It yet know antiemetic drug effective without ginger treat nausea cause chemotherapy . PURPOSE : This randomized phase II/III trial study give antiemetic drug together ginger see well work compare antiemetic drug alone treat nausea patient receive chemotherapy cancer .</brief_summary>
	<brief_title>Ginger Treating Nausea Patients Receiving Chemotherapy Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Compare efficacy 1 course ginger v placebo administer regimen contain 5-hydroxytryptamine type 3 ( 5-HT3 ) receptor antagonist antiemetic dexamethasone ( equivalent dose IV methylprednisolone ) control chemotherapy-related nausea course 2 chemotherapy patient cancer . - Compare efficacy 3 different dos ginger control chemotherapy-related nausea patient . - Determine adverse effect ginger give 3 day chemotherapy administration patient . - Determine adverse effect antiemetic regimen 4 day chemotherapy . - Compare chemotherapy-related anticipatory nausea patient treat antiemetic regimen . - Compare quality life 4 day chemotherapy patient treat antiemetic regimen . - Compare chemotherapy-related nausea course 3 chemotherapy patient 2 course ginger vs placebo . OUTLINE : This randomize , double-blind , placebo-controlled , multicenter study . Patients stratify accord participate center . Patients randomize 1 4 treatment arm . Day 1 course define day chemotherapy administration . - Placebo : Patients receive oral placebo twice daily day -3 3 chemotherapy course 2 3 . - 0.5g Ginger : Patients receive oral low-dose ginger oral placebo twice daily day -3 3 chemotherapy course 2 3 . - 1.0g Ginger : Patients receive oral intermediate-dose ginger oral placebo twice daily day -3 3 chemotherapy course 2 3 . - 1.5g Ginger : Patients receive oral high-dose ginger twice daily day -3 3 chemotherapy course 2 3 . Patients arm also continue receive schedule antiemetic regimen comprise 5-hydroxytryptamine type-3 ( 5-HT3 ) receptor antagonist ( ondansetron , granisetron , tropisetron , dolasetron mesylate ) dexamethasone ( DM ) ( equivalent dose IV methylprednisolone ( MePRDL ) ) day 1 course 2 3 . Symptoms assess day -3 day 1 course 2 3 day 1-4 course 1-3 . Quality life assess day 4 course 1-3 . Nausea vomit assess 4 time daily day 1-4 course 1-3 . PROJECTED ACCRUAL : A total 706 patient accrue study within 3 year .</detailed_description>
	<mesh_term>Nausea</mesh_term>
	<mesh_term>Vomiting</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis cancer schedule receive least 3 course chemotherapy Scheduled receive chemotherapy plan interruption radiotherapy surgery Chemotherapy course must separate least 2 week day 1 day 1 next course Must experience nausea degree severity completion first studyrelated course chemotherapy Received prior 5hydroxytryptamine type 3 ( 5HT3 ) receptor antagonist antiemetic ( ondansetron , granisetron , tropisetron , dolasetron mesylate ) dexamethasone ( DM ) give dose route ( equivalent dose IV methylprednisolone ( MePRDL ) ) day 1 course 1 chemotherapy Scheduled receive 5HT3 receptor antagonist antiemetic DM ( equivalent dose IV MePRDL ) day 1 course 2 3 chemotherapy No symptomatic brain metastasis PATIENT CHARACTERISTICS : Age : 18 Performance status : Not specify Life expectancy : Not specify Hematopoietic : Platelet count great 100,000/mm^3 second course chemotherapy No prior bleed blood coagulation disorder ( e.g. , thrombocytopenia platelet dysfunction ) Hepatic : No prior coagulation factor deficiency Renal : Not specify Cardiovascular : No prior vascular defect Other : Able understand English No concurrent impend bowel obstruction PRIOR CONCURRENT THERAPY : Biologic therapy : No concurrent interferon therapy Chemotherapy : See Disease Characteristics At least 6 month since prior chemotherapy Endocrine therapy : Not specify Radiotherapy : See Disease Characteristics No concurrent radiotherapy Surgery : See Disease Characteristics Other : No concurrent warfarin heparin therapeutic anticoagulation Concurrent lowdose warfarin maintenance venous access allow Concurrent rescue medication control symptom cause cancer treatment allow clinically indicate</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>nausea</keyword>
	<keyword>vomit</keyword>
</DOC>